Hepatic injury was not assessed in mice, but in a cohort of Angptl8-ASO treated rats, which also exhibited reduced hepatic steatosis and improved insulin sensitivity, no increase in plasma aspartate transaminase (AST) or ALT levels was observed, a well known side effect of ASO administration (Burel et al., 2016), which is discussed further below. Here, ANGPTL8 is linked to fatty liver disease.